semaglutide fda weight loss What's New in Obesity Treatment? The FDA's Decision to Ban

The active ingredient works the same way in your body whether it comes from a brand manufacturer or a compounding facility

REIMAGINE 2 was a 68-week efficacy and safety phase 3 trial of CagriSema 2.4 mg/2.4 mg and 1 mg/1 mg once-weekly versus semaglutide 2.4 mg, semaglutide 1 mg, cagrilintide 2.4 mg, and placebo in 2,713 adults with type 2 diabetes inadequately controlled with metformin with or without an SGLT2 inhibitor

Achieving and maintaining significant weight loss often leads to enhanced physical mobility, reduced joint pain, increased energy levels, and greater overall well-being

It is not recommended for those with certain conditions, such as a history of thyroid cancer or pancreatitis

This program helps uninsured or underinsured patients access medication for free if they meet certain criteria